Sharon Wu

982 citations

68 papers · 604 indexed · h-index 13

Impact in

Biochemistry top 10%
- Amino Acid Enzymes and Metabolism
Oncology top 10%
- Drug Transport and Resistance Mechanisms

Papers in ⓘ

Obstetrics and Gynecology 9
- Endometrial and Cervical Cancer Treatments 9
Oncology 29
- Cancer Immunotherapy and Biomarkers 7
- Drug Transport and Resistance Mechanisms 6

Co-authors: Houda Alachkar (11 shared papers)Yang Du (1 shared paper)David K. Ann (4 shared papers)Mojtaba Akhtari (5 shared papers)Ian S. Haworth (3 shared papers)Sarah F. Hamm‐Alvarez (3 shared papers)Michael B. Bolger (3 shared papers)Curtis T. Okamoto (3 shared papers)
Journals: Journal of Clinical Oncology (24 papers)Gynecologic Oncology (10 papers)Blood (3 papers)Journal of drug targeting (2 papers)Pharmaceutical Research (2 papers)
Partner nations: United States Italy Germany

In The Last Decade

Sharon Wu

55 papers receiving 599 citations

Peers

Countries citing papers authored by Sharon Wu

Since Specialization

Citations

This map shows the geographic impact of Sharon Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sharon Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sharon Wu more than expected).

Fields of papers citing papers by Sharon Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sharon Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sharon Wu. The network helps show where Sharon Wu may publish in the future.

Co-authors

The 25 scholars most cited alongside Sharon Wu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sharon Wu Line = papers co-authored together Sharon Wu links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 68 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Upregulation of the EMT marker vimentin is associated with poor clinical outcome in acute myeloid leukemia Journal of Translational Medicine ·Sharon Wu, Yang Du, John Beckford, Houda Alachkar	2018	101
2	Structure, Function, and Molecular Modeling Approaches to the Study of the Intestinal Dipeptide Transporter PepT1 Journal of Pharmaceutical Sciences ·Michael B. Bolger, Ian S. Haworth, Aaron K. Yeung, David K. Ann, Hermann von Grafenstein, Sarah F. Hamm‐Alvarez, Curtis T. Okamoto, Kwang-Jin Kim, Sujit K. Basu, Sharon Wu, Vincent H.L. Lee	1998	94
3	Molecular Identification of a Role for Tyrosine 167 in the Function of the Human Intestinal Proton- Coupled Dipeptide Transporter (hPepT1) Biochemical and Biophysical Research Communications ·Aaron K. Yeung, Sujit K. Basu, Sharon Wu, Chun Chu, Curtis T. Okamoto, Sarah F. Hamm‐Alvarez, Hermann von Grafenstein, Wei‐Chiang Shen, Kwang‐Jin Kim, Michael B. Bolger, Ian S. Haworth, David K. Ann, Vincent H.L. Lee	1998	57
4	Characterization of Mutations in the Mitochondrial Encoded Electron Transport Chain Complexes in Acute Myeloid Leukemia Scientific Reports ·Sharon Wu, Mojtaba Akhtari, Houda Alachkar	2018	31
5	miR-216b enhances the efficacy of vemurafenib by targeting Beclin-1, UVRAG and ATG5 in melanoma Cellular Signalling ·Meiying Luo, Long‐Fei Wu, Kexin Zhang, Hong Wang, Sharon Wu, Douglas O’Connell, Tongtong Gao, Hanbing Zhong, Yongfei Yang	2017	30
6	Apolipoprotein C2 - CD36 Promotes Leukemia Growth and Presents a Targetable Axis in Acute Myeloid Leukemia Blood Cancer Discovery ·Tian Yi Zhang, Jiawen Yang, Vijaya Vaikari, John Beckford, Sharon Wu, Mojtaba Akhtari, Houda Alachkar	2020	27
7	Biopharmaceutics of transmucosal peptide and protein drug administration: role of transport mechanisms with a focus on the involvement of PepT1 Journal of Controlled Release ·Vincent H.L. Lee, Chun Chu, Erik Denny Mahlin, Sujit K. Basu, David K. Ann, Michael B. Bolger, Ian S. Haworth, Aaron K. Yeung, Sharon Wu, Sarah F. Hamm‐Alvarez, Curtis T. Okamoto	1999	26
8	Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune‐checkpoint inhibitor‐related biomarkers Cancer ·Bassel Nazha, Tony Zhuang, Sharon Wu, Jacqueline T. Brown, Daniel Magee, Bradley Curtis Carthon, Ömer Küçük, Chadi Nabhan, Pedro C. Barata, Elisabeth I. Heath, Charles J. Ryan, Rana R. McKay, Viraj A. Master, Mehmet Asim Bilen	2023	21
9	Characterization of upregulated adhesion GPCRs in acute myeloid leukemia Translational research ·Jiawen Yang, Sharon Wu, Houda Alachkar	2019	19
10	Clinical and preclinical characterization of CD99 isoforms in acute myeloid leukemia Haematologica ·Vijaya Vaikari, Yang Du, Sharon Wu, Tian Yi Zhang, Klaus H. Metzeler, Aarif M.N. Batcha, Tobias Herold, Wolfgang Hiddemann, Mojtaba Akhtari, Houda Alachkar	2019	17
11	HER2 in Uterine Serous Carcinoma: Testing platforms and implications for targeted therapy Gynecologic Oncology ·Tenley Klc, Sharon Wu, Annelise Wilhite, Nathaniel Jones, Matthew A. Powell, Alex Olawaiye, Eugenia Girda, Jubilee Brown, Allison Puechl, Rouba Ali‐Fehmi, Ira Winer, Thomas J. Herzog, W. Michael Korn, Britt Erickson	2022	14
12	Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER Molecular Cancer Therapeutics ·Jeff Hsu, Colin Chong, Jeffrey Serrill, Levina Goon, Joan Balayan, Eric N. Johnson, Grachelle Lorenzana, Sharon Wu, Kevin G. Leong, Theodore J. Yun, Yong Wang, Faming Jiang, Lynne Bannen, Peter Lamb, Wei Xu, Peiwen Yu	2022	12
13	Differential outcomes and immune checkpoint inhibitor response among endometrial cancer patients with MLH1 hypermethylation versus MLH1 “Lynch-like” mismatch repair gene mutation Gynecologic Oncology ·Michael Toboni, Sharon Wu, Alex Farrell, Joanne Xiu, Jennifer R. Ribeiro, Matthew J. Oberley, Rebecca C. Arend, Britt Erickson, Thomas J. Herzog, Premal H. Thaker, Matthew A. Powell	2023	12
14	The mitochondrial transcription machinery genes are upregulated in acute myeloid leukemia and associated with poor clinical outcome SHILAP Revista de lepidopterología ·Sharon Wu, Nicole Fahmy, Houda Alachkar	2019	12
15	Dihydroorotate Dehydrogenase Inhibitors: Quantitative Structure-activity Relationship Analysis Pharmaceutical Research ·Shijun Ren, Sharon Wu, Eric J. Lien	1998	11
16	A single-institution retrospective analysis of outcomes for stage I–II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy Leukemia & lymphoma ·Michael S. Binkley, Susan M. Hiniker, Sharon Wu, Yasodha Natkunam, Erik Mittra, Ranjana H. Advani, Richard T. Hoppe	2015	11
17	Fine tuning of rabbit equilibrative nucleoside transporter activity by an alternatively spliced variant Journal of drug targeting ·Sharon Wu, David K. Ann, Kwang‐Jin Kim, Vincent H.L. Lee	2005	9
18	HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis Gynecologic Oncology ·Shaina F. Bruce, Sharon Wu, Jennifer R. Ribeiro, Alex Farrell, Matthew J. Oberley, Ira Winer, Britt Erickson, Tenley Klc, Nathaniel Jones, Premal H. Thaker, Matthew A. Powell	2023	8
19	XL092, a multi-targeted inhibitor of MET, VEGFR2, AXL and MER with an optimized pharmacokinetic profile European Journal of Cancer ·Jeff Hsu, Colin Chong, Leanne Goon, Joan Balayan, Sharon Wu, Eric N. Johnson, Grachelle Lorenzana, Lynne Bannen, Linh T. Nguyen, Christian Scheffold, Peter Lamb, Wei Xu, Peiwen Yu	2020	8
20	Assessment of the roles of Spt5-nucleic acid contacts in promoter proximal pausing of RNA polymerase II Journal of Biological Chemistry ·Roberta Dollinger, Eilene B. Deng, Josie Schultz, Sharon Wu, Haley R. Deorio, David S. Gilmour	2023	6

About Sharon Wu

Sharon Wu is a scholar working on Obstetrics and Gynecology, Oncology, Cancer Research, Hematology and Pulmonary and Respiratory Medicine, having authored 68 papers that have together received 604 indexed citations. Recurring topics across this work include Endometrial and Cervical Cancer Treatments (9 papers), Acute Myeloid Leukemia Research (7 papers), Cancer Immunotherapy and Biomarkers (7 papers), Cancer Genomics and Diagnostics (7 papers), Drug Transport and Resistance Mechanisms (6 papers), Prostate Cancer Treatment and Research (5 papers), Histone Deacetylase Inhibitors Research (5 papers) and Genetic factors in colorectal cancer (4 papers). The work is most often cited by research in Biochemistry (77 citations), Oncology (247 citations), Physiology (38 citations), Cancer Research (113 citations) and Hematology (53 citations). Sharon Wu has collaborated with scholars based in United States, Italy and Germany. Frequent co-authors include Houda Alachkar, Yang Du, David K. Ann, Mojtaba Akhtari, Ian S. Haworth, Sarah F. Hamm‐Alvarez, Michael B. Bolger, Curtis T. Okamoto, Hermann von Grafenstein and Sujit K. Basu. Their work appears in journals such as Journal of Clinical Oncology, Gynecologic Oncology, Blood, Journal of drug targeting and Pharmaceutical Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact